High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.
Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significance.Bone marrow-...
Main Authors: | Normann Steiner, Roman Hajek, Sabina Sevcikova, Bojana Borjan, Karin Jöhrer, Georg Göbel, Gerold Untergasser, Eberhard Gunsilius |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5519162?pdf=render |
Similar Items
-
The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.
by: Normann Steiner, et al.
Published: (2018-01-01) -
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
by: Normann Steiner, et al.
Published: (2020-08-01) -
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
by: Bojana Borjan, et al.
Published: (2020-01-01) -
Vasohibin inhibits angiogenic sprouting <it>in vitro </it>and supports vascular maturation processes <it>in vivo</it>
by: Gunsilius Eberhard, et al.
Published: (2009-08-01) -
Long Non-Coding RNAs in Multiple Myeloma
by: Romana Butova, et al.
Published: (2019-01-01)